Identification of K-ras Mutation in a Patient With Non-small Cell Lung Cancer Treated With Chemoradiation Therapy and Panitumumab: A Possibility to Personalize Cancer Therapy

Abstract

RTOG 0839 is a Phase II study of pre-operative chemoradiation therapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NSCLC). The investigatory agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody. Although K-ras mutations have been shown to be predictive to anti-EGFR therapy in colorectal cancer, it is unknown if they predict benefit to anti-EGFR therapy in combination with chemoradiation for Stage III NSCLC. The purpose of this report is to identify a NSCLC patient with a KRAS mutation who had a partial pathologic response, with disappearance of K-ras mutant clone.